Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance, Ipsogen to Co-market Their Flagship Products in New Pharmacogenomic Alliance

NEW YORK, Nov. 16 (GenomeWeb News) - Genaissance Pharmaceuticals and Ipsogen will co-market their flagship technologies to offer gene-expression and genotyping technologies to cancer-based drug makers, the firms said today.


Specifically, the collaboration will jointly market Genaissance's haplotyping and high-throughout genotyping technologies, and Ipsogen's Oncogenomic platform, used for gene-expression profiling.


Financial terms were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.